Scientific Research Publishing3d
Adolescent-Onset Triple-Antibody Positive Juvenile Dermatomyositis Found in Hispanic Male Wrestler: A Case Report and Literature Review ()
Sanghavi, R. , Tesmer, P. , Singh, D. and Sukumaran, S. (2025) Adolescent-Onset Triple-Antibody Positive Juvenile ...
Dr. Rajeev Ardey - Understanding Arthritis And Joint Pain
Arthritis is a broad term that refers to the inflammation of joints resulting in joint pain, swelling, stiffness and limited range of motion.
PMLiVE3d
EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases
Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...
Dunfermline Press4d
Dunfermline cafe: Bela's Cakes holds grand opening today
Bela's Cakes opens at 9 am today, offering a selection of Izabela's popular goodies. In the coming months, she hopes to expand and offer vegan and gluten-free options too. For more information on Bela ...
Swedish Orphan Biovitrum AB: US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant (emapalumab-lzsg)
Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) ...
US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg)
Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult ...
The Pharma Letter5d
Celltrion wins EC approval for Avtozma, a biosimilar to RoActemra
South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...
Hosted on MSN6d
EC authorises Celltrion’s Avtozma for multiple indications
The approval allows Avtozma to be used for the same range of conditions as RoActemra: moderate to severely active rheumatoid ...
PharmiWeb6d
Celltrion receives EC Approval for Avtozma® (CT-P47), a biosimilar to RoActemra® (tocilizumab)
Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab). Avtozma® has been approved for ...